Celldex Therapeutics, Inc. (CLDX)Healthcare | Biotechnology | Hampton, United States | NasdaqCM
29.43 USD
-0.46
(-1.539%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
After hours: 29.43 |
Hot Take ↕ | Oct. 10, 2026, 10:59 a.m. EDT
The investment case here is fractured by a stark disconnect between analyst optimism and the company's deteriorating reality. While analysts project a massive upside to $64, the underlying business is failing; revenue has collapsed by 97% year-over-year, and the company is burning cash with no path to profitability visible in the immediate future. The price history confirms this structural decay, showing a nearly 58% drop over the last nine years, capped recently by another annual decline. This is not a value trap; it is a valueless asset waiting for a catalyst that hasn't materialized yet. The options market reflects this anxiety, with traders buying deep out-of-the-money puts to protect against further ruin while speculating on a miracle approval. Without a confirmed clinical success or a pivot to revenue generation, the risk of permanent capital loss outweighs the theoretical upside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.096905 |
| AutoETS | 0.116155 |
| AutoARIMA | 0.116155 |
| MSTL | 0.126000 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 1.69 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.024 |
| Excess Kurtosis | 0.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.686 |
| Revenue per Share | 0.002 |
| Market Cap | 2,311,124,224 |
| Forward P/E | -6.95 |
| Beta | 0.90 |
| Website | https://www.celldex.com |
As of Oct. 10, 2026, 10:59 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest at strikes significantly below the current price (e.g., $15, $25), indicating a fear of further downside or a 'catapult' scenario where the stock drops to test deep support. Conversely, there is notable call activity at distant strikes ($45, $55, $65) suggesting a speculative bet on a binary event driving the price higher, but the overall sentiment leans toward hedging against a decline rather than aggressive bullish accumulation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.11182475 |
| Address1 | Perryville III Building |
| Address2 | Suite 220 53 Frontage Road |
| All Time High | 3,375.0 |
| All Time Low | 1.5 |
| Ask | 29.38 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,869,090 |
| Average Daily Volume3 Month | 1,326,703 |
| Average Volume | 1,326,703 |
| Average Volume10Days | 1,869,090 |
| Beta | 0.896 |
| Bid | 25.54 |
| Bid Size | 1 |
| Board Risk | 1 |
| Book Value | 9.103 |
| City | Hampton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 29.43 |
| Current Ratio | 11.821 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 30.025 |
| Day Low | 28.99 |
| Debt To Equity | 0.686 |
| Display Name | Celldex Therapeutics |
| Dividend Date | 1,549,843,200 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -322,432,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.957 |
| Enterprise To Revenue | 10,116.716 |
| Enterprise Value | 1,598,441,088 |
| Eps Current Year | -4.12389 |
| Eps Forward | -4.23664 |
| Eps Trailing Twelve Months | -4.42 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 908 454 1911 |
| Fifty Day Average | 37.5302 |
| Fifty Day Average Change | -8.100201 |
| Fifty Day Average Change Percent | -0.21583153 |
| Fifty Two Week Change Percent | 11.182475 |
| Fifty Two Week High | 45.14 |
| Fifty Two Week High Change | -15.709999 |
| Fifty Two Week High Change Percent | -0.34802833 |
| Fifty Two Week Low | 22.1 |
| Fifty Two Week Low Change | 7.33 |
| Fifty Two Week Low Change Percent | 0.3316742 |
| Fifty Two Week Range | 22.1 - 45.14 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 516,547,800,000 |
| Float Shares | 73,018,329 |
| Forward Eps | -4.23664 |
| Forward P E | -6.9465427 |
| Free Cashflow | -133,080,496 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 198 |
| Fullday Change | -0.45999908 |
| Fullday Change Percent | -1.5389732 |
| Fullday Price | 29.43 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -278,648,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00271 |
| Held Percent Institutions | 1.10273 |
| Implied Shares Outstanding | 78,529,532 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.avantimmune.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,549,843,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey. |
| Long Name | Celldex Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,311,124,224 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_9620565 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -300,548,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,444,624,331 |
| Number Of Analyst Opinions | 14 |
| Open | 29.61 |
| Operating Cashflow | -235,566,000 |
| Operating Margins | -3,664.682 |
| Overall Risk | 1 |
| Payout Ratio | 0.0 |
| Phone | 908 200 7500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 29.43 |
| Post Market Time | 1,791,835,258 |
| Previous Close | 29.89 |
| Price Eps Current Year | -7.136466 |
| Price Hint | 2 |
| Price To Book | 3.2330003 |
| Price To Sales Trailing12 Months | 14,627.368 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.705 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | -0.459999 |
| Regular Market Change Percent | -1.53897 |
| Regular Market Day High | 30.025 |
| Regular Market Day Low | 28.99 |
| Regular Market Day Range | 28.99 - 30.025 |
| Regular Market Open | 29.61 |
| Regular Market Previous Close | 29.89 |
| Regular Market Price | 29.43 |
| Regular Market Time | 1,791,835,201 |
| Regular Market Volume | 596,401 |
| Return On Assets | -0.27617002 |
| Return On Equity | -0.43877 |
| Revenue Growth | -0.97 |
| Revenue Per Share | 0.002 |
| Sand P52 Week Change | 0.17318833 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 78,529,532 |
| Shares Percent Shares Out | 0.1402 |
| Shares Short | 11,006,720 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 8,641,597 |
| Short Name | Celldex Therapeutics, Inc. |
| Short Percent Of Float | 0.1663 |
| Short Ratio | 6.0 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CLDX |
| Target High Price | 100.0 |
| Target Low Price | 28.0 |
| Target Mean Price | 63.07143 |
| Target Median Price | 64.0 |
| Total Cash | 717,587,008 |
| Total Cash Per Share | 9.138 |
| Total Debt | 4,904,000 |
| Total Revenue | 158,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 32.46235 |
| Two Hundred Day Average Change | -3.0323486 |
| Two Hundred Day Average Change Percent | -0.09341125 |
| Type Disp | Equity |
| Volume | 596,401 |
| Website | https://www.celldex.com |
| Zip | 8,827 |